Merck Serono and Compugen have established Neviah Genomics, a start-up company focused on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity. Neviah Genomics will operate out of the Merck Serono Israel Bioincubator. Merck Serono Ventures will provide the unit’s initial funding, while Compugen will utilize certain proprietary predictive discovery technologies and receive an equity ownership in the new company and a right to royalties from potential...